New hope for advanced stomach cancer: experimental combo targets tumors after first-line failure
NCT ID NCT07361991
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called IBI363, which helps the immune system attack cancer cells, combined with other drugs (bevacizumab with or without nab-paclitaxel) as a second treatment for people with advanced stomach cancer. About 50 adults aged 18-75 whose cancer worsened after initial therapy will participate. The goal is to check safety and see if the combination shrinks tumors or slows disease progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVAN'CE'D are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug combo targets Hard-to-Treat GI cancers
- Custom-Made vaccine aims to boost immune attack on kidney tumors
- New drug cocktail aims to tackle Hard-to-Treat stomach cancer
- New drug duo takes aim at hard-to-treat stomach cancer with liver metastases
- New drug cocktail aims to fight tough stomach cancer
- New pill combo aims to fight stomach cancer when first treatment fails